Authors
Pedro C Barata, Ulka Vaishampayan, Wenxin Xu
Published in
Clinical advances in hematology & oncology : H&O. Volume 24. Issue 7 Suppl 11. Pages 1-12.
Abstract
The management of renal cell carcinoma (RCC) continues to evolve as new combinations and therapeutic strategies are demonstrating benefit across lines of therapy. For patients with resectable clear cell RCC (ccRCC), options for adjuvant therapy now include pembrolizumab as a single agent or in combination with the hypoxiainducible factor 2α (HIF-2α) inhibitor belzutifan. For patients with metastatic ccRCC, the preferred first-line treatment options are a combination of a tyrosine kinase inhibitor (TKI) and immunotherapy (IO) (axitinib + pembrolizumab, cabozantinib + nivolumab, or lenvatinib + pembrolizumab) or dual IO with ipilimumab + nivolumab. TKI-based therapy remains the standard treatment approach for patients with progression after IO. A single-agent TKI (cabozantinib, tivozanib, or axitinib) is an appropriate option for many patients with post-IO progression, although the more intensive combination of lenvatinib + everolimus may be considered for selected patients. Proactive management of toxicities is essential for maximizing outcomes with TKI-based therapy. Belzutifan has conventionally been used in the third-line setting, although the LITESPARK-011 trial demonstrated a progression-free survival improvement but no overall survival improvement with belzutifan + lenvatinib over single-agent cabozantinib in the post-IO setting; this regimen has been recently approved by the United States Food and Drug Administration. Novel HIF-2α inhibitors and other investigational strategies may further change the treatment landscape in the future.
PMID:
43007401
Bibliographic data and abstract were imported from PubMed on 11 Nov 2026.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0